Nanobodies Targeting SARS-CoV-2 Papain-Like Protease: Dual Antiviral and Anti-Inflammatory Activity

Study overview

The PubMed record identifies a J Virol publication titled “Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.” From the title alone, the study addresses small single-domain antibody fragments (nanobodies) that target the viral papain-like protease (PLpro) of SARS-CoV-2, and it claims both antiviral and anti-inflammatory activities.

The supplied PubMed excerpt does not include the article abstract or the primary data. Therefore, the only confirmed factual elements available from the provided source are the study focus as stated in the title and the complete bibliographic and author-affiliation metadata contained in the PubMed record.

Publication and citation details

• Journal: Journal of Virology (J Virol)
• Publication date: 2026 Sep 22; volume 100, issue 9, article e0059926.
• DOI: 10.1128/jvi.00599-26.
• Electronic publication date (Epub): 2026 Aug 28.

These bibliographic elements are reported in the PubMed entry and are verifiable via the DOI and journal citation listed in the record.

Authors and contributing institutions

The PubMed entry lists multiple authors, including Guolong Liu, Jiantao Chen, Fang Wu, Peilan Wei, Yuzhe Wu, Di Yan, Xinfeng Xu, Qiang Ding, Yanqun Wang, Shuwen Liu, Jincun Zhao, and Wei Xu, among others. Several authors are indicated as having contributed equally.

Affiliated institutions reported in the PubMed metadata include:

• Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
• NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
• Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, China.
• Guangdong Provincial Center for Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangzhou, China.
• State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
• Center for Infection Biology, School of Basic Medical Sciences, Tsinghua University, Beijing, China.

These affiliations indicate a multi-institutional collaboration primarily among Chinese research centers focused on drug discovery, pathogen detection, respiratory disease, and infectious-disease control.

Central claim from the title

The article title communicates a dual claim: that nanobodies targeting SARS-CoV-2 PLpro demonstrate both antiviral activity (presumably by inhibiting a viral protease) and anti-inflammatory effects (presumably by modulating host inflammatory pathways). This duality is the principal message conveyed by the published title in the PubMed record.

No further experimental context, quantitative outcomes, or mechanistic detail is included in the available excerpt; the title alone establishes the target (PLpro) and the two outcome domains (antiviral and anti-inflammatory).

Available metadata from the PubMed record

The PubMed excerpt provided includes standard site navigation text, the Atypon full-text link to the journal, bibliographic citation, DOI, author list with multiple affiliations, and notation of equal contribution for several authors. The record includes a link to the full text via the journal platform.

Missing information and limitations in the provided excerpt

The supplied PubMed excerpt does not contain:

• The article abstract or background rationale.
• Methods: experimental design, model systems (in vitro, in vivo, or clinical), sample sizes, controls, or assays used.
• Results: quantitative antiviral efficacy, measures of anti-inflammatory effect, statistical analyses, or comparative benchmarks.
• Safety, pharmacokinetic, or toxicology data.
• Conclusions beyond the title statement, discussion, or limitations as presented by the authors.
• Conflict-of-interest or funding statements beyond the bibliographic header (grants and funding sections are accessible on the full record but were not included in the excerpt supplied).

Because these elements are absent from the excerpt, any detailed interpretation of efficacy, translatability to clinical practice, or regulatory implications would be speculative and is not supported by the provided source material.

Accessing the full text and next steps for clinical review

The PubMed record links to the journal full text on the Atypon platform (J Virol). For clinicians, researchers, or guideline developers seeking to evaluate the study rigorously, the following actions are required and feasible via the full article:

• Retrieve and review the abstract, methods, and results to confirm experimental models, measured endpoints, and statistical robustness.
• Assess whether antiviral and anti-inflammatory effects were demonstrated in vitro, in animal models, or in human studies.
• Examine dosing, delivery format, pharmacokinetics, and safety data where reported.
• Review authors’ discussion, limitations, conflicts of interest, and funding sources.

Until the full-text content is consulted, clinical or translational conclusions cannot be drawn from the PubMed excerpt alone. The DOI 10.1128/jvi.00599-26 and the Atypon link in the PubMed record should be used to obtain the complete article for detailed evaluation.